Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Not Confirmed
Not Confirmed
28 October-01 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Industry Trade Show
Not Confirmed
28 October-01 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
16 Nov 2023
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-urges-acrotech-speed-up-study-cancer-drugs-2023-11-16/
24 Nov 2022
// INDIANPHARMAPOST
https://www.indianpharmapost.com/news/evive-enters-license-agreement-with-acrotech-biopharma-to-commercialize-ryzneuta-in-us-13335
24 Sep 2021
// Z. Brennan ENDPTS
https://endpts.com/fdas-cancer-drug-advisors-will-review-2-more-dangling-accelerated-approvals-for-multiple-myeloma-leukemia/
26 Apr 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210426005126/en/Acrotech-Biopharma-Announces-the-Publication-of-Data-From-a-Phase-1-Study-of-BELEODAQ%C2%AE-belinostat-Combined-With-Standard-CHOP-Bel-CHOP-in-Patients-With-Previously-Untreated-Peripheral-T-cell-Lymphoma
26 Apr 2021
// BUSINESSWIRE
Details:
The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Lead Product(s): Pralatrexate
Therapeutic Area: Oncology Brand Name: Folotyn
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CASI Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Brand Name : Folotyn
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2023
Details:
The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Lead Product(s): Belinostat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Onxeo
Deal Size: $6.6 million Upfront Cash: $6.6 million
Deal Type: Agreement April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Onxeo
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $6.6 million
April 06, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?